Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine

37Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Langerhans cell histiocytosis (LCH) is a rare disorder which frequently involves the lungs of affected adults. Recent evidence suggests it is a clonal neoplastic disorder. Prognosis in this disease is variable, but in its multisystem form or when associated with progressive respiratory dysfunction, prognosis is poor. Recent case reports and a phase II trial of the antimonocyte drug 2-chlorodeoxyadenosine (2CDA) have described success in treating LCH. We used 2CDA to treat a young Australian man with LCH involving lungs and bone. A complete symptomatic remission was achieved with no evidence of recurrence some 5 years after completion of chemotherapy.

Cite

CITATION STYLE

APA

Goh, N. S. L., McDonald, C. F., MacGregor, D. P., Pretto, J. J., & Brodie, G. N. (2003). Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Respirology, 8(1), 91–94. https://doi.org/10.1046/j.1440-1843.2003.00427.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free